SCHEMBL14634281

SCHEMBL14634281

Cc1ccc(Nc2ncc(-c3n[nH]c4c(F)cc(F)cc34)c(N)n2)cc1S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.39
CDK2 P24941 3/20 0.39
LCK P06239 2/20 0.39
KDR P35968 2/20 0.39
JAK3 P52333 2/20 0.39
JAK2 O60674 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
PDPK1 O15530 1/20 0.39
DAPK3 O43293 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
CHEK2 O96017 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
NTRK1 P04629 1/20 0.39
PRKCG P05129 1/20 0.39
INSR P06213 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468378 0.90 CDK1 (0.39) CDK1CDK2LCKKDRJAK3
SCHEMBL14633720 0.88 CDK2 (0.39) CDK1CDK2LCKKDRJAK3
SCHEMBL2472742 0.88 JAK2 (0.40) CDK1CDK2LCKKDRJAK3
SCHEMBL2468759 0.87 NTRK1 (0.44) CDK1CDK2LCKKDRJAK3
SCHEMBL2466308 0.86 GRM4 (0.41) CDK1CDK2LCKKDRJAK3
SCHEMBL14633591 0.83 MEN1 (0.39) KDRJAK3FLT3ALKSGK1
SCHEMBL14634241 0.82 KDR (0.40) CDK1KDRJAK3LYNFLT3
SCHEMBL14633971 0.81 SGK1 (0.39) CDK1CDK2LCKKDRJAK3
SCHEMBL14633488 0.81 GRM4 (0.49) NTRK1ITKNTRK2CLK4SGK1
SCHEMBL14634243 0.80 SGK1 (0.40) JAK3JAK2NTRK1LYNSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CDK1 36/4885CDK2 22/4885LCK 127/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CDK1 7/4885CDK2 1/4885LCK 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.